

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Research Agreement between the University of Michigan and Decibel Therapeutics, Inc.

Action Requested: Authorization to enter into Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Research and Sponsored Projects while reviewing the Proposal Approval Form which then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by the Board and agreed to by the parties involved.

This proposed research agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Professor Gabriel Corfas is an employee of the University of Michigan (“University”), and a partial owner of Decibel Therapeutics, Inc. The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Gabriel Corfas, PhD, a Professor in the Department of Otorhinolaryngology, is a partial owner of a for-profit company called Decibel Therapeutics, Inc. (the “Company”). The Company wishes to fund a project entitled, “CTSU NSS Decibel Project 2019 Aminoglycoside-Induced Bilateral Vestibulopathy Identification and Testing” (ORSP #20-PAF01235) in the Department of Neurology under the direction of Dr. Kevin Kerber. The purpose of this project is to collect data about the clinical presentation, treatment regimens, functional outcomes, and demographics of patients with aminoglycoside-induced bilateral vestibulopathy.

Agreement Terms:

The terms of the Agreement conform to University policy. The period of performance for the project is approximately one (1) year. The amount of funding support will not exceed \$116,118. Since research projects are often amended, this agreement includes provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreement will support an effort by Dr. Kerber to use his expertise and University laboratory, as well as other University resources, to collect data about the clinical presentation, treatment regimens, functional outcomes, and demographics of patients with aminoglycoside-induced bilateral vestibulopathy for the Company.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University's entering into this Agreement with Decibel Therapeutics, Inc.

Respectfully submitted,



Rebecca Cunningham
Vice President for Research

October 2020